亚甲蓝治疗缺血性脑卒中的研究进展

Progress in the therapeutic use of methylene blue in ischemic stroke

脑卒中作为全球高致死、高致残的疾病,一直被广泛研究。亚甲蓝作为一种被美国食品药品管理局(FDA)批准用于治疗高铁血红蛋白血症和氰化物中毒的药物已有一百二十余年,而在近期研究中发现其具有神经保护作用,并在缺血性脑卒中的动物模型中展现出良好的保护作用。我们就近年来亚甲蓝治疗缺血性脑卒中的研究进行简要综述。

Stroke has been widely studied as a highly lethal and highly disabling disease worldwide.Methylene blue approved by the Food and Drug Administration(FDA)of the United States has been used in the treatment of methemoglobinemia and cyanide poisoning for more than one hundred and twenty years.In recent studies,it has been found to have neuroprotective effects and is effective in a few of animal models of ischemic stroke.This article briefly reviews the recent research on the therapeutic use of methylene blue in ischemic stroke.